Compare Elastic NV (ESTC) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elastic NV vs Novo Nordisk A/S — how do they compare? Elastic NV trades at $76.21 (market cap $7.94B), while Novo Nordisk A/S trades at $46.26 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 26.2× Elastic NV's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Elastic NV pays none. Which is the better fit depends on your goals.
| ESTC | NVO | |
|---|---|---|
Market Cap | $7.94B | $207.85B |
Sector | Technology | Health |
52-Week High | $94.47 | $63.98 |
52-Week Low | $43.30 | $35.29 |
Enterprise Value | $7.16B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Elastic (ESTC) trades at $75.88, down 0.58% on the day, with a bullish technical outlook supported by moving averages and strong institutional interest. Recent earnings beats and a projected net profit margin of 21.14% for 2026 highlight improving fundamentals, while collaborations with OpenAI and AWS security distinctions underscore strategic growth. The stock faces headwinds from high valuation multiples and a negative net income in 2025.
The outlook remains positive given analyst consensus and product innovations, but risks include elevated P/E and EV/EBITDA ratios, potential legal scrutiny, and competitive pressures. Upside is supported by a $106 high price target, though investor caution is warranted near-term due to overbought RSI levels.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
